Mapping the Certolizumab Pegol Epitope on Tumor Necrosis Factor and Comparison With Infliximab, Adalimumab, and Etanercept

被引：0
|
作者：
Henry, Alistair
Gong, Hai Ping
Nesbitt, Andrew N.
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S630 / S630
页数：1
相关论文
共 50 条
  • [31] Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor at agents
    Nesbitt, Andrew
    Fossati, Gianluca
    Bergin, Marianne
    Stephens, Paul
    Stephens, Sue
    Foulkes, Roly
    Brown, Derek
    Robinson, Martyn
    Bourne, Tim
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (11) : 1323 - 1332
  • [32] Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab.
    Raynauld, Jean-Pierre
    Bessette, Louis
    Choquette, Denis
    Fortin, Isabelle
    Haraoui, Boulos
    Pelletier, Jean-Pierre
    Remillard, Marie-Anais
    Sauvageau, Diane
    Villeneuve, Edith
    Coupal, Louis
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1123 - S1123
  • [33] TNF binding by certolizumab pegol, adalimumab, and infliximab-stoichiometry, complex formation, and the biologic effects of complexes
    Henry, Alistair
    Kennedy, Jeff
    Fossati, Gianluca
    Nesbitt, Andrew
    CLINICAL IMMUNOLOGY, 2007, 123 : S169 - S170
  • [34] Neutralization of soluble and membrane tumor necrosis factor-α (TNF-α) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-α receptor-specific bioassays
    Gramlick, Amie
    Fossati, Gianluca
    Nesbitt, Andrew M.
    GASTROENTEROLOGY, 2006, 130 (04) : A697 - A697
  • [35] Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View
    Hu, Shi
    Liang, Shuaiyi
    Guo, Huaizu
    Zhang, Dapeng
    Li, Hui
    Wang, Xiaoze
    Yang, Weili
    Qian, Weizhu
    Hou, Sheng
    Wang, Hao
    Guo, Yajun
    Lou, Zhiyong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (38) : 27059 - 27067
  • [36] Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes
    Fossati, G
    Nesbitt, AM
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S298 - S299
  • [37] Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
    Hochberg, MC
    Tracy, JK
    Hawkins-Holt, M
    Flores, RH
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 13 - 16
  • [38] Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab
    Wallis, RS
    Ehlers, S
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) : 34 - 38
  • [39] Crohn's disease - infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-α treatment
    Schreiber, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (34-35) : 1770 - 1774
  • [40] Typicality of the amino acid sequences of certolizumab pegol, adalimumab, and infliximab with respect to naturally occurring human immunoglobulin sequences
    Martin, Andrew C.
    Tyson, Kerry
    Page, Matt J.
    Snowden, James R.
    Fossati, Gianluca
    Raghavan, Abhimandan K.
    Lawson, Alastair D.
    Nesbitt, Andrew M.
    Popplewell, Andrew G.
    GASTROENTEROLOGY, 2007, 132 (04) : A449 - A449
12345